Tr1X

Tr1X, Inc. is a biotechnology company developing universal allogeneic cell therapies to treat autoimmune and inflammatory diseases. Their therapies are based on engineered Tr1 cells, derived from universal donors, offering a potential cure instead of lifelong treatment. Tr1X has a scalable GMP-grade manufacturing process to produce these therapies at commercial volume.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $75M

Date: 17-Jan-2024

Investors: The Column Group, NEVA SGR, Alexandria Ventures

Markets: Biotechnology, Cell Therapy, Immunotherapy

HQ: San Diego, California, United States

Founded: 2018

Website: https://www.tr1x.bio/

LinkedIn: https://www.linkedin.com/company/tr1x

Twitter:

Instagram: